Northwestern Mutual Wealth Management Co. Acquires Shares of 3,056 Illumina, Inc. $ILMN

Northwestern Mutual Wealth Management Co. acquired a new position in shares of Illumina, Inc. (NASDAQ:ILMN) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 3,056 shares of the life sciences company’s stock, valued at approximately $537,000.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. Evolve Private Wealth LLC bought a new stake in Illumina during the 2nd quarter worth about $1,864,000. Korea Investment CORP bought a new position in Illumina during the second quarter worth about $16,149,000. EP Wealth Advisors LLC acquired a new position in shares of Illumina in the second quarter valued at approximately $726,000. Rakuten Securities Inc. acquired a new position in shares of Illumina during the second quarter worth about $33,000. Finally, Ieq Capital LLC acquired a new position in Illumina during the second quarter worth $47,111,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In other news, SVP Christensen Jakob Wedel sold 1,033 shares of the firm’s stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $191.52, for a total transaction of $197,840.16. Following the completion of the transaction, the senior vice president owned 14,023 shares of the company’s stock, valued at approximately $2,685,684.96. This trade represents a 6.86% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Scott M. Davies sold 615 shares of Illumina stock in a transaction on Thursday, July 30th. The stock was sold at an average price of $200.00, for a total transaction of $123,000.00. Following the transaction, the insider owned 20,338 shares in the company, valued at approximately $4,067,600. This trade represents a 2.94% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,874,458 shares of company stock valued at $367,996,424 in the last quarter. 2.90% of the stock is currently owned by corporate insiders.

Illumina Stock Down 0.1%

Shares of ILMN opened at $224.84 on Thursday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.40 and a current ratio of 1.80. Illumina, Inc. has a 52 week low of $88.00 and a 52 week high of $227.70. The stock has a market capitalization of $33.95 billion, a price-to-earnings ratio of 41.95, a PEG ratio of 3.17 and a beta of 1.45. The stock has a fifty day moving average of $191.66 and a 200-day moving average of $154.42.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. Illumina had a return on equity of 29.84% and a net margin of 18.36%.The business had revenue of $1.16 billion during the quarter, compared to analysts’ expectations of $1.13 billion. During the same quarter in the prior year, the firm earned $1.19 EPS. The business’s revenue for the quarter was up 9.4% compared to the same quarter last year. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. As a group, sell-side analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of analyst reports. Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research report on Friday, July 31st. Guggenheim increased their target price on Illumina from $200.00 to $226.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Piper Sandler reissued an “overweight” rating and issued a $225.00 price objective (up from $200.00) on shares of Illumina in a research note on Monday, August 3rd. JPMorgan Chase & Co. raised their target price on Illumina from $220.00 to $230.00 and gave the company an “overweight” rating in a report on Friday, July 31st. Finally, Weiss Ratings upgraded Illumina from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, June 3rd. One analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $188.40.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.